Nov 07, 2023 / 06:10PM GMT
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Great. So welcome to the fireside chat with Incyte this afternoon. My name is Michael Schmidt. I'm a biotech analyst with Guggenheim. It's my great pleasure to welcome Herve Hoppenot, CEO; as well as Jim Lee, who heads the [IAI] portfolio at Incyte. Welcome, and thanks for joining us.
Herve Hoppenot - Incyte Corporation - CEO & Chairman
Well, thanks for inviting us.
James H. Lee - Incyte Corporation - Group VP, Head of Inflammation & AutoImmunity Group
Thank you. Nice to be here.
Questions and Answers:
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MDSo maybe just starting out with a broader question. We'd like to focus on the IAI portfolio today, perhaps more so than oncology. But with Opzelura, you've sort of set the stage to the commercial product launching at the moment to expand your